All In Biotech

Drug Trial Radar · NCT00776009

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Last checked: Nov 19, 2026Latest source record: Jun 8, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Oct 2008

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

  • Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)Drug

    10 mg and/or 20 mg capsules

  • PlaceboDrug

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-doseTime frame: Pre-dose to 10, 11, and 12 hours post-dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Center, LLC

    Little Rock, Arkansas

  • Florida Clinical Research Center, LLC

    Bradenton, Florida

  • Miami Research Associates

    South Miami, Florida

  • Vince and Associates Clinical Research

    Overland Park, Kansas

  • Center for Psychiatry and Behavioral Medicine, Inc.

    Las Vegas, Nevada

  • Bayou City Research

    Houston, Texas

  • Claghorn-Lesem Research Clinic

    Houston, Texas

  • Behavioral Neurology

    Lubbock, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.